← Back to Search

Social Network Encouragement for Colon Cancer Screening

N/A
Recruiting
Led By Francesca Gany, MD, MS
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial seeks to see if peer outreach training increases colorectal cancer screening in Black communities, where screening rates are lower than white communities. #ColorectalCancerAwareness

Who is the study for?
This trial is for Black men, aged 45-75, who have completed FIT testing in the past year. Participants must speak English or French fluently and have at least five close male peers over 45 years old. Men with a household member already in the study cannot join.
What is being tested?
The study tests if training individuals to encourage their peers to undergo colorectal cancer screening (FIT testing) increases screening rates. It compares outcomes of those given both peer outreach training and CRC education versus those receiving only CRC education.
What are the potential side effects?
Since this trial involves educational interventions rather than medical treatments, there are no direct physical side effects expected from participating in this study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: FITx3 intervention and CRC educationExperimental Treatment1 Intervention
Provide CRC education, SN education, handouts and text message/social media posts example library. Monthly Telephone Support Provide any additional support to index participants for peer FIT testing, assist in completion of peer outreach tracker. Biweekly Text Messages. Follow-up Assessment (month 8 after intervention) Complete follow-up form and assist in completion of peer outreach tracker Provide reminders to encourage participants to encourage peers to get FIT tested.
Group II: Colorectal Cancer (CRC) education aloneActive Control1 Intervention
All participants will be educated, on a simplified clinical and medical background of CRC; causes and risk factors for CRC; eligibility criteria for screening; lifestyle modifications to lower risk of developing CRC; screening methods for CRC, including FIT and colonoscopy; addressing myths and misconceptions about CRC; and information about resources for low-cost and no-cost screening, screening for the uninsured and screening for those without legal immigration documentation. Participants will also be educated on elements of fecal immunochemical testing (detects signs of cancer in the stool, can be done at home and sent to a laboratory for analysis, needs to be done yearly to ensure maximal effectiveness for cancer screening). Follow-up Assessment at 8 months complete follow-up form and assist in completion of peer outreach tracker Provide reminders to encourage participants to encourage peers to get FIT tested.

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,969 Previous Clinical Trials
597,279 Total Patients Enrolled
CANCER PREVENTION FUNDUNKNOWN
Francesca Gany, MD, MSPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
8 Previous Clinical Trials
3,075 Total Patients Enrolled

Media Library

Peer Outreach Clinical Trial Eligibility Overview. Trial Name: NCT05793593 — N/A
Colon Cancer Screening Research Study Groups: Colorectal Cancer (CRC) education alone, FITx3 intervention and CRC education
Colon Cancer Screening Clinical Trial 2023: Peer Outreach Highlights & Side Effects. Trial Name: NCT05793593 — N/A
Peer Outreach 2023 Treatment Timeline for Medical Study. Trial Name: NCT05793593 — N/A
~10 spots leftby Mar 2025